Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 350,900 shares, a decline of 37.9% from the October 15th total of 565,500 shares. Based on an average daily volume of 281,500 shares, the days-to-cover ratio is currently 1.2 days. Currently, 7.6% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Virpax Pharmaceuticals Stock Up 4.0 %

Shares of VRPX stock traded up $0.02 during mid-day trading on Thursday, hitting $0.64. The company’s stock had a trading volume of 106,472 shares, compared to its average volume of 1,806,374. Virpax Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $8.00. The business has a 50-day moving average price of $0.68 and a 200 day moving average price of $0.96.

Virpax Pharmaceuticals (NASDAQ:VRPX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.75) EPS for the quarter.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.